SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
Quick Read KO and ABBV anchor the portfolio at 25% each, rated Very Safe with payout ratios under…
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both…
2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts
It’s safe to say the healthcare sector isn’t renowned as a repository of dividend-paying companies. Yet some not…
Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
If You Have $500,000 Saved at 60, Here’s The Sort of Monthly Income You Can Count On
Verizon (VZ) yields 5.4% at its current price, paying $0.69 per quarter and offering higher current income for…
Buying This Healthcare Stock Could Make You a Millionaire Retiree
AbbVie has a solid business capable of performing well even in bad times. The company has proven that…
1 Major Factor Behind the Healthcare Sector’s Recent Surge
Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
AbbVie parts ways with Calico
Unexpected uncoupling raises questions about the pace – and patience – of longevity drug discovery amid shifting pharma…
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.
Skyrizi and Rinvoq sales are pushing AbbVie’s sales higher. UnitedHealth Group raised its full-year guidance and is rebounding…
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…